FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ adenocarcinoma. IMAB362 is a chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells by activation of immune effector mechanisms. IMAB362 has demonstrated single-agent activity and was safe and tolerable in patients (pts) with pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by IHC (validated CLAUDETECT18.2 Kit). Eligible pts had a CLDN18.2 expression of ≥ 2+ in ≥ 40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX..

In Situ FTIR Reactor for Monitoring Gas-Phase Products during a (Photo)catalytic Reaction in the Liquid Phase

International audienc

High-Visible-Light Photoactivity of Plasma-Promoted Vanadium Clusters on Nanozeolites for Partial Photooxidation of Methanol

International audienceCold VCl3–plasma is employed for the preparation of highly dispersed vanadium oxide clusters on nanosized zeolite. Different types of zeolites, such as EMT, FAU (z.X), and Beta, are used. The activity of the prepared catalysts is studied in the selective photooxidation of methanol under polychromatic visible and UV irradiations. The physicochemical properties and catalytic performance of plasma-treated zeolite Beta (P-V2O5@Beta) catalyst is compared with zeolite Beta (V2O5@Beta) and amorphous silica (V2O5@SiO2) impregnated vanadium oxide catalysts. Pure V2O5 is used as a reference material. The set of catalytic data shows that plasma-prepared zeolite Beta based catalyst displays the highest activity. Complementary characterization techniques including XRD, N2-sorption, FTIR, ionic exchange, pyridine adsorption, Raman, NMR, TPR, and EDX-TEM are used to study the impact of the preparation approach on the physicochemical properties and catalytic performance of photocatalysts

Synthesis of silica-polymer core-shell hybrid materials with enhanced mechanical properties using a new bifunctional silane-based photoinitiator as coupling agent

International audienceHere, we report the use of new bifunctional silane-based type-1 photoinitiator (SPI-1) as a coupling agent for photopolymer filler and silica grafting. The SPI-1 is grafted on the surface of silica nanoparticles via interactions between the ethoxy group of the silane and the silanol groups of the silica surface. The grafted particles are then dispersed or embedded in/with acrylate polymer by a direct photopolymerization process. The materials were characterized using different techniques including UV–vis spectroscopy, FTIR, TGA, and TEM. Their mechanical properties and the surface morphology were also investigated using AFM and DMA analyses. A significant change and enhancement of the mechanical properties of the newly synthesized materials were observed with respect to that of the unmodified silica. The analysis of the morphology at the microscale level reveals interesting information on the origin of this enhancement and on the dispersion of the filler in the polymer matrix

Synthesis of silica-polymer core-shell hybrid materials with enhanced mechanical properties using a new bifunctional silane-based photoinitiator as coupling agent

International audienc

High-Visible-Light Photoactivity of Plasma-Promoted Vanadium Clusters on Nanozeolites for Partial Photooxidation of Methanol

Cold VCl₃–plasma is employed for the preparation of highly dispersed vanadium oxide clusters on nanosized zeolite. Different types of zeolites, such as EMT, FAU (z.X), and Beta, are used. The activity of the prepared catalysts is studied in the selective photooxidation of methanol under polychromatic visible and UV irradiations. The physicochemical properties and catalytic performance of plasma-treated zeolite Beta (P-V₂O₅@Beta) catalyst is compared with zeolite Beta (V₂O₅@Beta) and amorphous silica (V₂O₅@SiO₂) impregnated vanadium oxide catalysts. Pure V₂O₅ is used as a reference material. The set of catalytic data shows that plasma-prepared zeolite Beta based catalyst displays the highest activity. Complementary characterization techniques including XRD, N₂-sorption, FTIR, ionic exchange, pyridine adsorption, Raman, NMR, TPR, and EDX-TEM are used to study the impact of the preparation approach on the physicochemical properties and catalytic performance of photocatalysts

Validation of the Series Power Couplers of the LIPAc SRF Linac

International audienceIn the framework of the IFMIF/EVEDA project, the cryomodule of the Linear IFMIF Prototype Accelerator (LIPAc) will be assembled then tested at Rokkasho in 2019. Eight Series Power Couplers (PC) operating at 175 MHz were manufactured under a CEA contract, in order to equip this Cryomodule. They were all successfully RF conditioned up to 100 kW CW in TW and SW configurations. All the high RF power tests were performed under CIEMAT responsibility in BTESA Company premises, according to the CEA requirements. In order to fix difficulties encountered during the fab process, manufacturing and quality control have been analyzed in depth. Thanks to the corrective actions implemented, every PC reached the performances targeted for qualification. This paper will give details about this manufacturing phase and provide an overview of the obtained RF test results

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

The selective MEK1/2 inhibitor pimasertib has shown anti-tumour activity in a pancreatic tumour model. This phase I/II, two-part trial was conducted in patients with metastatic pancreatic adenocarcinoma (mPaCa) (NCT01016483). In the phase I part, oral pimasertib was given once daily discontinuously (5 days on/2 days off treatment) or twice daily continuously (n = 53) combined with weekly gemcitabine (1,000 mg/m2 ) in 28-day cycles to identify the recommended phase II dose (RP2D) of pimasertib. In the phase II part, patients were randomised to pimasertib (RP2D) or placebo plus weekly gemcitabine (n = 88) to investigate progression-free survival (PFS), overall survival (OS) and safety. The RP2D was determined to be 60 mg BID. PFS and OS outcomes did not indicate any treatment benefit for pimasertib over placebo in combination with gemcitabine (median PFS 3.7 and 2.8 months, respectively, HR = 0.91, 95% CI: 0.58-1.42: median OS 7.3 vs. 7.6 months, respectively). KRAS status did not influence PFS or OS. The incidence of grade ≥3 adverse events was 91.1% and 85.7% for pimasertib/gemcitabine and placebo/gemcitabine respectively, but there was a higher incidence of ocular events with pimasertib/gemcitabine (28.9% vs. 4.8% for placebo/gemcitabine). In conclusion, no clinical benefit was observed with first-line pimasertib plus gemcitabine compared with gemcitabine alone in patients with mPaCa.status: publishe